Home » Stocks » MSON

Misonix, Inc. (MSON)

Stock Price: $16.76 USD -0.37 (-2.16%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 291.48M
Revenue (ttm) 67.61M
Net Income (ttm) -20.37M
Shares Out 17.22M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $16.76
Previous Close $17.13
Change ($) -0.37
Change (%) -2.16%
Day's Open 17.05
Day's Range 16.53 - 17.56
Day's Volume 29,021
52-Week Range 6.71 - 20.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

FARMINGDALE, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhanc...

GlobeNewsWire - 3 weeks ago

FARMINGDALE, N.Y., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and rege...

GlobeNewsWire - 1 month ago

FARMINGDALE, N.Y., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhanc...

GlobeNewsWire - 2 months ago

FARMINGDALE, N.Y., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhanc...

GlobeNewsWire - 2 months ago

FARMINGDALE, N.Y., Dec. 18, 2020 (GLOBE NEWSWIRE) -- 2020) – Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products tha...

GlobeNewsWire - 3 months ago

FARMINGDALE, N.Y., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhanc...

GlobeNewsWire - 3 months ago

FARMINGDALE, N.Y., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhanc...

Seeking Alpha - 3 months ago

Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q1 2021 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

FARMINGDALE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and rege...

GlobeNewsWire - 4 months ago

FARMINGDALE, N.Y., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhanc...

GlobeNewsWire - 4 months ago

Confirms Improving Revenue Trends, Rise in Procedure Volumes and Strong New Product Adoption Confirms Improving Revenue Trends, Rise in Procedure Volumes and Strong New Product Adoption

GlobeNewsWire - 5 months ago

Expands Misonix’s Wound Tissue Regeneration Franchise and Complements Nexus SonicOne® Strategy Expands Misonix’s Wound Tissue Regeneration Franchise and Complements Nexus SonicOne® Strategy

GlobeNewsWire - 5 months ago

FARMINGDALE, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that e...

Seeking Alpha - 5 months ago

Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q4 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of Misonix (NASDAQ:MSON) were flat in after-market trading after the company reported Q4 results.

GlobeNewsWire - 5 months ago

FARMINGDALE, N.Y., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and r...

GlobeNewsWire - 6 months ago

FARMINGDALE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that en...

GlobeNewsWire - 7 months ago

FARMINGDALE, N.Y., July 30, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that en...

GlobeNewsWire - 7 months ago

Full Year Revenue of Approximately $62.3 Million

Seeking Alpha - 9 months ago

Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

With Focus on Maintaining Our Objective of Shareholder Value Creation,  Company to Prioritize Cash Preservation Through Expense Reduction,  Workforce Efficiency and Operational Synergies

InvestorPlace - 1 year ago

No matter which strategy is employed or what types of stocks are sought after, investors want to see returns. The post 7 ‘Strong Buy’ Stocks With Over 50% Upside Potential appeared first on ...

Other stocks mentioned: BYSI, EQT, ESTE, EVFM, PLYA, SQNS
Seeking Alpha - 1 year ago

Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

FARMINGDALE, N.Y., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc.  (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and ...

GlobeNewsWire - 1 year ago

FARMINGDALE, N.Y., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and re...

GlobeNewsWire - 1 year ago

Reiterates Expectation for Fiscal 2020 Full Year Pro Forma Revenue Growth of 20% Reiterates Expectation for Fiscal 2020 Full Year Pro Forma Revenue Growth of 20%

GlobeNewsWire - 1 year ago

FARMINGDALE, N.Y., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc.  (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and ...

Seeking Alpha - 1 year ago

Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

FARMINGDALE, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that ...

GuruFocus - 1 year ago

Misonix Inc (NASDAQ:MSON) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019.

Seeking Alpha - 1 year ago

Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q4 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

Misonix (NASDAQ: MSON) releases its next round of earnings this Wednesday, August 14.

Seeking Alpha - 1 year ago

Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Misonix' (MSON) CEO Stavros Vizirgianakis on Acquisition of Solsys Medical - Transcript

Benzinga - 1 year ago

Medical device maker Misonix, Inc. announced Thursday that it entered a definitive agreement to acquire privately held Solsys Medical, LLC in an all-stock transaction valued at about $97 million.

About MSON

Misonix, together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleans... [Read more...]

Industry
Medical Devices
IPO Date
Jan 23, 1992
CEO
Stavros George Vizirgianakis
Employees
254
Stock Exchange
NASDAQ
Ticker Symbol
MSON
Full Company Profile

Financial Performance

In 2020, Misonix's revenue was $62.48 million, an increase of 60.84% compared to the previous year's $38.85 million. Losses were -$17.42 million, 135.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Misonix stock is "Strong Buy." The 12-month stock price forecast is 21.00, which is an increase of 25.30% from the latest price.

Price Target
$21.00
(25.30% upside)
Analyst Consensus: Strong Buy